Open-Label Adalimumab for Ulcerative Colitis Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Ulcerative Colitis
Interventions
DRUG

Adalimumab

The loading dose will be 160 mg. A dose of 80 mg will be given at Week 2 and 40 mg every other week starting at Week 4 until completion at Week 24. If it is found that they are not responding to 40 mg of adalimumab at Week 8 or later, the dose may be increased to 40 mg weekly.

Trial Locations (3)

55905

Mayo Clinic, Rochester

60637

University of Chicago, Chicago

85259

Mayo Clinic, Scottsdale

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT00421642 - Open-Label Adalimumab for Ulcerative Colitis Patients | Biotech Hunter | Biotech Hunter